



**Evidence Standards for Insurance Coverage of Diagnostic Tests for
Alzheimer’s Disease
Policy Development Group (PDG)**

PDG Participant Name and Affiliation
<p>Mark Bondi, PhD, ABPP/CN Professor of Psychiatry, University of California at San Diego (UCSD), School of Medicine Staff Neuropsychologist, VA San Diego Healthcare System</p>
<p>Robin Cisneros National Director, Medical Technology Assessment and Products, Kaiser Permanente</p>
<p>Joshua T. Cohen, PhD Deputy Director, Center for the Evaluation of Value and Risk in Health Research Associate Professor of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center</p>
<p>Howard Feldman, MD, FRCP Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience, Bristol-Myers Squibb</p>
<p>G. Scott Gazelle, MD, MPH, PhD Director, Institute for Technology Assessment Professor in Radiology, Harvard Medical School Professor, Department of Health Policy and Management, Harvard School of Public Health</p>
<p>David Holtzman, MD Associate Director, Alzheimer’s Disease Research Center, Washington University Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology Professor of Developmental Biology, Washington University School of Medicine</p>
<p>Bradley T. Hyman, MD, PhD Director, Massachusetts Alzheimer's Disease Research Center Director, Alzheimer’s Unit, MGH Institute for Degenerative Disease John B. Penney Jr. Professor of Neurology, Harvard Medical School</p>
<p>Kejal Kantarci, MD, MSc Associate Consultant Division of Neuroradiology Associate Professor of Radiology, Mayo Clinic</p>
<p>Jason Karlawish, MD Associate Professor of Medicine, University of Pennsylvania School of Medicine Associate Director, Penn Memory Center Director, Alzheimer’s Disease Center’s Education and Information Transfer Core</p>

<p>Robert McDonough, MD Senior Medical Director, Clinical Research and Policy Development Aetna, Inc.</p>
<p>Mark Mintun, MD Chief Medical Officer Avid Radiopharmaceuticals, Inc. (a division of Eli Lilly)</p>
<p>Jeffrey R. Petrella, MD Associate Professor of Radiology, Duke University Medical Center</p>
<p>Creighton H. Phelps, PhD Director, Alzheimer's Disease Centers Programs, Division of Neuroscience, National Institute on Aging (NIA)/ National Institutes of Health (NIH)</p>
<p>Murray Raskind, MD Director, Mental Health Services, VA Puget Sound Health Care System Professor and Vice-Chair, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine</p>
<p>James Rollins, MD Director, Division of Items and Devices, Coverage & Analysis, Office of Clinical Standards and Quality (OCSQ), Centers for Medicare and Medicaid Services (CMS)</p>
<p>Alan Rosenberg, MD Vice President of Medical and Clinical Pharmacy Policy, Wellpoint, Inc.</p>
<p>Reisa A. Sperling, MD, MMSc Director, Center for Alzheimer's Research and Treatment Director, Education and Information Transfer Core, Massachusetts Alzheimer's Disease Research Center Co-Leader, Neuroimaging Program, Massachusetts Alzheimer's Disease Research Center Associate Professor of Neurology, Harvard Medical School</p>
<p>William H. Thies, PhD Chief Medical and Scientific Officer, Alzheimer's Association</p>
<p>Kathleen Welsh-Bohmer, PhD, ABCN Director, Bryan Alzheimer's Disease Research Center Professor of Psychiatry and Behavioral Sciences and Assistant Professor in Medicine, Duke University School of Medicine</p>
<p>Kristine Yaffe, MD Chief of Geriatric Psychiatry and Director of the Memory Disorders Clinic, San Francisco VA Medical Center Roy and Marie Scola Endowed Chair in Psychiatry; Associate Chair of Clinical and Translational Research; Professor, Department of Psychiatry, Neurology, and Epidemiology and Biostatistics, University of California at San Francisco</p>
<p>Eric Yuen, MD Vice President and Head of Clinical Development Johnson & Johnson - Janssen Alzheimer Immunotherapy</p>